This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk05: Welcome to the Dexcom second quarter 2022 earnings release conference call. My name is Darrell and I'll be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session. During the question and answer session, if you have a question, please press 01 on your touchtone phone. As a reminder, this conference is being recorded. I will now turn the call over to Shawn Christensen. Shawn, you may begin.
spk16: Thank you, Operator, and welcome to Dexcom's second quarter 2022 earnings call. Our agenda begins with Kevin Sayre, Dexcom's chairman, president, and CEO, who will summarize our recent highlights and ongoing strategic initiatives, followed by a financial review and outlook from Jeremy Sylvain, our chief financial officer. Following our prepared remarks, we will open the call up for your questions. At that time, we ask analysts to limit themselves to one question so we can provide an opportunity for everyone participating today. Please note that there are also slides available related to our second quarter performance on the Dexcom Investor Relations website on the events and presentations page. With that, let's review our safe harbor statement. Some of the statements we will make in today's call may constitute forward-looking statements. These statements reflect management's intentions, beliefs, and expectations about future events, strategies, competition, products, operating plans, and performance. All forward-looking statements included in this presentation are made as of the date hereof based on information currently available to Dexcom, are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in the forward-looking statements. The factors that could cause actual results to differ materially from those expressed or implied by any of these forward-looking statements are detailed in Dexcom's annual report on Form 10-K, most recent quarterly report on Form 10-Q, and other filings with the Securities and Exchange Commission. Except as required by law, we assume no obligation to update any such forward-looking statements after the date of this presentation or to conform these forward-looking statements to actual results. Additionally, during the call, we will discuss certain financial measures that have not been prepared in accordance with GAAP with respect to our non-GAAP and cash-based results. Unless otherwise noted, all references to financial metrics are presented on a non-GAAP basis. The presentation of this additional information should not be considered in isolation or as a substitute for results or superior to results prepared in accordance with GAAP. Please refer to the tables in our earnings release and the slides accompanying our second quarter earnings presentation for a reconciliation of these measures to their most directly comparable GAAP financial measures. Now, I will turn it over to Kevin.
spk11: Thank you, Sean, and thank you, everyone, for joining us. Today, we reported another strong quarter for Dexcom with second quarter organic revenue growth of 16% compared to the second quarter of 2021. Momentum for global CGM adoption remains high, and we once again achieved worldwide record new customer starts in the second quarter. Following some disruption early in the year related to the Omicron wave, office access has continued to improve, and we experienced a return to a more normalized customer journey, which helped us deliver this record Customer satisfaction also continues to reach new levels as our U.S. Net Promoter Score hit another all-time record in the second quarter. Our customers value the differentiated experience that Dexcom provides with consistent praise for our real-world accuracy, connectivity, actionable features, and customer support. Product performance has been a hallmark for Dexcom throughout our history. Customers and caretakers alike rely upon the accuracy of Dexcom CGM and can be confident in performance across all aspects of glucose management, backed by numerous clinical trials and borne out by real-world experience. We have long viewed software as an avenue to differentiate, enabling unique user experiences, supporting greater connectivity, and enhancing our ability to move more seamlessly into new markets. In support of this vision, We have invested significantly in building our software infrastructure in recent years and now spend more of our R&D budget on software than hardware. A tangible example of this can be found in our rollout of Dexcom 1. This product leverages our G6 hardware and will use our G7 platform in the future, but uses software to provide a different experience than our G-series systems. This has allowed us to meaningfully expand our market presence in recent months. entering new markets and winning tenders internationally that were previously not available to our G-Series product. This is just the beginning of our journey on leveraging software to create products that meet the needs of our end users. Our software infrastructure has also positioned us to be the partner of choice for technology companies looking to build new and innovative experiences around CGM data. Our list of real-time API partners continues to grow. as we're the only company that can provide partners real-time CGM data in an FDA-regulated solution. Our software capabilities are also laying the foundation for our success beyond the intensively managed population. For example, two partners focused on the use of CGM for weight management and metabolic health, Cygnos and Levels Health, have clinical trials underway that are leveraging our real-time API capabilities. We are excited to see the outcome from these trials as they provide a glimpse into the future for CGM technology that could serve as a much broader end market than today. The second quarter saw a number of strategic accomplishments in international markets that continue to strengthen our competitive position. The excitement continues to grow for our portfolio of CGM systems, G6, G7, and Dexcom 1, and we've made significant strides in both direct and distributor markets to broaden access to our technology. We launched Dexcom 1 in both Spain and the UK and have secured reimbursement for key segments of the population, opening large parts of these markets that previously lacked reimbursement for Dexcom CGM. We also announced a partnership with Roche to distribute Dexcom 1 in Italy. This relationship will allow us to leverage Roche's well-established commercial infrastructure to bring Dexcom 1 to a much larger Italian market. In Australia, the government recently committed to providing subsidized access to our G6 system for all people living with type 1 diabetes, which is a significant improvement in coverage and a great win for Australians deserving access to CGM technology. Our limited launch of G7 in the UK continues to be met with significant enthusiasm from our customers, who have provided consistently positive feedback on product size, ease of use, the shorter warm-up time, the app experience, and more. Many customers shared that they would often forget they were even wearing the G7 during their session and indicated they can't wait to continue wearing the product full-time in the future. The period has proven to be incredibly valuable, allowing us to assess the functionality of the sensor and app in a real-world setting, and providing feedback on ways to refine our support system to make the broader rollout as streamlined as possible. We are excited to get G7 in the hands of more customers and plan to expand our launch in the third quarter starting in the U.K. In the US, our 510K submission for G7 remains under review with the FDA. As part of this process, we are making a subtle change to the G7 software based on feedback from the FDA, slightly delaying our expected timelines for clearance and US launch. We expect FDA clearance and a limited launch later this year and a large commercial launch in the US in the first quarter of 2023. Encouragingly, our preliminary discussions with payers have progressed very well. They understand what this product will mean for our customers and people with diabetes broadly, giving us increasing confidence in the ability to ramp up commercial coverage quickly. Finally, we were very proud to showcase our expanded CGM portfolio at two of the largest diabetes conferences of the year, ATDD in Barcelona and ADA in New Orleans. These events provide us an opportunity to connect with thought leaders across the diabetes space. and we continue to see a clear consensus on real-time CGM being the standard of care in diabetes management and a growing appreciation of the health and economic benefits of extending the use of this technology beyond the intensively managed population, including the broader type 2 population and use in the hospital. Between these two events, there were dozens of presentations, abstracts, and posters highlighting success stories of CGM to date and what the future could hold for this technology. I started attending diabetes conferences almost 30 years ago. As I look back even two or three years ago, these types of conversations around the broad potential of CGM were nonexistent. Now it's become very apparent that CGM data will become the basis of where diabetes management and glucose control in the future is headed. We're very excited about the opportunities they have for Dexcom. And with that, I'll turn it over to Jeremy for a review of the second quarter financials.
spk06: Jeremy? Thank you, Kevin. As a reminder, unless otherwise noted, the financial metrics presented today will be discussed on a non-GAAP basis. Reconciliations to GAAP can be found in today's earnings release as well as on our IR website. For the second quarter of 2022, we reported worldwide revenue of $696 million, which included $12 million of unfavorable foreign currency impact. This is compared to $595 million for the second quarter of 2021, which represents growth of 16% on an organic basis. We have slightly changed our definition of organic revenue based on feedback from our stakeholders to exclude currency and acquisition-related revenue in the trailing 12-month period. Volume growth for the second quarter came in around the mid-30% range on a global basis. U.S. revenue totaled $511 million for the second quarter, compared to $462 million in the second quarter of 2021, representing growth of 11%. Customer demand remains strong in the U.S., and our unit volume growth continued to grow at a very healthy clip this quarter, relatively in line with recent quarters. We have been launching a number of new tools for our sales force in the U.S. that leverage technology to make each physician visit more efficient and effective. These tools inform our team what each doctor is prescribing, the makeup of their payer mix, and even comparative out-of-pocket costs for each customer. This data can make each visit more impactful and help us continue to address the competitive myths that still exist in the market. We continue to see an ongoing impact from revenue growth from our strategic shift to the pharmacy channel, but as discussed previously, we believe this will ultimately set us up to serve meaningful more customers over time. International revenue grew 39%, totaling $185 million in the second quarter. Organic revenue growth was 34% for the second quarter. Our positive momentum continued this quarter as the number of global initiatives we implemented in the past year has significantly improved our competitive position in international markets. In addition to the Dexcom 1 new market wins Kevin highlighted before, we also continued to drive greater reimbursement in our initial launch countries in Eastern Europe this quarter. While we previously announced that patient reimbursement in Bulgaria and Estonia was Latvia and Lithuania have now established full or partial reimbursement for individuals with type 1 diabetes. This is a great example of how our CGM portfolio strategy can help us enter completely new markets and be a catalyst for access. Through new product launches and reimbursement efforts over the past 18 months, we are happy to share that we have increased the reimbursed access to our product by more than 3 million customers and look forward to getting this much-needed technology in the hands of as many people as possible. Our second quarter gross profit was $449.5 million, or 64.6% of revenue, compared to 70.1% of revenue in the second quarter of 2021. Given the initial launch of G7 in the UK, this is the first quarter where G7 development costs started to flow through COGS, accounting for some of the expected year-over-year step-down in gross margin. Additionally, there were greater than 50 basis points of impact from currency in the quarter. Our second quarter gross margin was a nice step up from the first quarter and leaves us on track to hit our margin targets for the full year. Operating expenses were $347.6 million for Q2 of 2022 compared to $315 million in Q2 of 2021. Similar to last quarter, we generated meaningful operating expense leverage despite incremental investment to support the G7 launch. We saw OPEX as a percentage of sales this quarter drop by 310 basis points year over year as we continue to leverage our R&D and G&A expense lines. Operating income was 101.9 million or 14.6% of revenue in the second quarter of 2022 compared to 101.5 million or 17.1% of revenue in the same quarter of 2021. As a tough year over year gross margin comp, was partially offset by operating leverage in the quarter. Adjusted EBITDA was $175.5 million, or 25.2% of revenue for the second quarter compared to $156.6 million, or 26.3% of revenue for the second quarter of 2021. Net income for the second quarter was $69.5 million, or $0.17 per share. We remain in a great financial position, closing the quarter with approximately $2.8 billion worth of cash and cash equivalents. This provides us the flexibility to continue to invest in our organic growth opportunity, including the ongoing build-out this year of our Malaysia manufacturing facility, and to assess any compelling strategic investments that present themselves. Along those lines, we announced today a $700 million share repurchase program, which will allow us to offset the dilutive impact from our 2023 convertible notes. We are always assessing the best uses of our capital, and given the recent market pressure, we view this as a great time to invest in our own business as we remain incredibly bullish on the sizable opportunity ahead for Dexcom. Turning to guidance, we are updating our full-year 2022 revenue guidance to a range of $2.86 to $2.91 billion. For margins, we are reaffirming our prior full-year guidance of gross profit margins of approximately 65%, operating margins of approximately 16%, and adjusted EBITDA margins of approximately 25%. This guidance factors in a significant uptick in currency headwinds relative to the expectations we shared a quarter ago. We now expect around $40 million of foreign currency headwinds for the full year relative to our prior estimate of around $15 to $20 million. With that, I will pass it back to Kevin.
spk11: Thanks, Jeremy. As I look at this quarter, our underlying fundamentals remain incredibly strong. We experienced another quarter of solid volume growth, achieved worldwide record new customer starts, recorded our highest ever customer satisfaction rating. These results were before any material contribution from G7, which we expect to improve the customer experience in every way possible. We advanced our CGM portfolio outside the United States with a wider rollout of Dexcom 1, helping us reach more reimbursed lives and serving more new customers. For G7, the feedback from our limited launch in the UK has been fantastic, leaving us incredibly excited for a broader global launch in the coming weeks. And in the US, we now have clear visibility to the finish line on G7 clearance. Our preliminary payer discussions are setting the stage for a big launch early next year. Despite all the macroeconomic challenges that exist today, runaway inflation, supply chain challenges, FX headwinds, we reiterated our margin guidance, continue to have no delivery delays across our business, and remain committed to driving additional operating leverage in the coming years. And finally, we announced a $700 million share repurchase plan today. This will allow us to offset the dilutive impact of our 2023 convertible notes and also provide us an opportunity to send a clear message We're betting on ourselves and the mass opportunity ahead of us. We're optimistic as we've ever been about our future. With that, I'd now like to open up the call for Q&A.
spk16: Sean? Thank you, Kevin. As a reminder, we ask our audience to limit themselves to only one question at this time and then re-enter the queue if necessary. Operator, please provide the Q&A instructions.
spk05: And if anyone has a question, you can press 01 on your touchtone phone. Once again, if you have a question, it's 01 on your touchtone phone. And our first question comes from Robbie Marcus from J.P. Morgan. Go ahead, Robbie.
spk13: Great. Thanks for taking the question. You know, it was when you filed G7 last year, you had a pretty high degree of confidence in the completeness of the filing. So... One, wondering if we could get a little more on what it is with the software, what you have to change, and how different it's going to be from the European version. What gives you that level of confidence and how to think about U.S. sales growth until we get a G7 launch? Thanks.
spk11: You know, Robbie, this is Kevin. I'll take the G7 questions. The software visions relate to the management of the alerts and alarms in the U.S. app. FDA had some questions about some of the things that we had done and put in it. We discussed several options that we had. We decided the best option at this time was to revise the software and file it differently, and we've added a few other features to it as well based on our discussions with them. We're in the middle of revising the software for that and have to run it through the complete validation verification process and resubmit. We're not done with it yet, but we're working very quickly to get done with that, and that's really our big major issue. We've talked through everything else. We did have a strong level of confidence, and we still do, in our relationships and our discussions with the FDA on G7. The one thing we've figured out as we've been through this process is we changed absolutely everything. We changed the algorithm. We changed the insertion techniques. We changed every manufacturing process. you know, procedure that we have and completely rewrote the entire app and the software experience, which is a lot for them to digest and a lot for us to submit. You know, if I look at learnings for us over time, I think we'll probably do things a little more incrementally going forward rather than as big as this one was, and we can get things through faster. But we're, you know, we're in a good spot. We have a lot of clarity as to where we need to go going forward, and I'll let Robby handle the growth issues regarding G6 because we're still doing extremely well with that product. I'm not Robbie. Jeremy, go ahead.
spk06: Yeah. Hey, how you doing, Robbie? Thanks for the question. So in the U.S., you know, look, the quarter here we had about 11% growth. You know, that's generally due to some of what we talked about in prior quarters, us getting into physicians' offices. And, you know, as those new patients didn't hit those record levels, you ultimately see that recur in a recurring business model such as ours. It plays through. What gives us a lot of confidence for the back half of the year is Q2 was a record, and we're back on that record track, and we do expect strength for the rest of the year to the point where we expect U.S. growth rates to accelerate in Q3 and Q4 as we come off of this quarter where we see these record new patient starts. And quite frankly, we expect to have record new patient starts going forward for the balance of the year, even without G7. So I hope that gives you that question. We're very confident in G6, and obviously we're even more confident in G7 once that launches.
spk05: And our next question comes from Jeff Johnson from Baird. Go ahead, Jeff.
spk10: Thank you. Kevin, I just want to go back on your comments about revising some of the software on the alerts and alarms. on the G7 product. So it sounds like to me you're still in the process of that, but I think you also said in your prepared remarks that you were comfortable that you would still have a limited launch in the fourth quarter and a fuller launch in the first quarter of 2023 in the U.S. So, you know, one, can I just confirm that's what you said? Two, do you have some better certainty on all the other aspects of the filing from the FDA that gives you that ability to draw that line in the sand, or at least where's your confidence on that timeline? Thank you.
spk11: We do have great certainty on the other components of the filing with the FDA. We've talked through all the other questions and things that we've discussed and we're very, very comfortable with that. So really the outstanding major item is revision and filing of the revised software after we validated and verified all that. So we are very, very comfortable with that. And yes, what I did say is we are anticipating a limited launch. in the fourth quarter in the U.S. and in the full-on rollout early in the year in 2023. You know, one of the things I also said in my prepared remarks is we're very bullish about the progress we've made with the payers as far as getting the G7 reimbursed because they can see how important it's going to be for our patient base. So on the one hand, while we have the delay in the approval and the launch, none of us, we'd all like to be faster. The other thing we're seeing on the other side There's a lot of cooperation in the payer community and just in the channel in getting this in position for reimbursement very quickly after approval so we can get the launch out in not too different of a timeframe on a reimburse basis from what we expected in the beginning. So those two factors together, again, add to where we think we are.
spk05: And our next question comes from Margaret Kaiser from William Blair. Go ahead, Margaret.
spk07: Hey, good afternoon, guys. Thanks for taking the question. Yeah, I wanted to maybe dive a little bit further into kind of this new patient ad growth, just because it's important as we get into 23 as well. But any details that you can give in terms of how it looks like within T1, T2 intensive, and others, and if there have been any changes, I guess, in the last six or 12 months, you know, are things getting harder, easier, you know, and, you know, what kind of efforts can you guys put in place to to re-accelerate more meaningfully those new patient ads. Thanks.
spk06: Sure. Yeah, I can answer that. And thank you for the question. You know, what we saw, and I think this is, we've really talked about it, is we found our folks are most effective when they're able to get into physicians' offices. That's always been the case, and it's continued to show itself time and time again. And so what we've found is it rises all, you know, tides once we're able to do so. But the predominance of where our new patient ads are coming If you want to kind of see what the more accelerant is, it's really in the type two intensive space. As we get into more primary care physicians offices, these are folks we've called on really for the first time as we've expanded our sales force in 2021. Getting there in person has really unlocked that market and that's what you continue to see. And so now our focus is, and we talked about it a little bit in the prepared remarks, now that we're in these offices, a record new patient quarter this quarter, certainly That's encouraging. But we're also seeing that all of these tools that have been put in place means every call, every visit, every time we're in the office, we're able to be more effective about what might be the prescriber's decision-making around that particular patient. And through doing that, whether it's debunking myths around co-pays and what the out-of-pocket is and making sure folks understand the cost, whether it's the ease of use and showing folks that a majority of our patients are able to put it on and use either a training online or simple training in the box to ultimately put it on their body. What we're really finding is we're breaking down all of those myths out there, and our sales force continues to get more and more effective. So we're going to continue to do that over time, and we're seeing that continue to play out as better prescriber patterns, more prescriptions per provider, and more providers coming over to prescribing Dexcom. So all of those are playing out, which is what gives us confidence for acceleration in the U.S. in the back half of the year.
spk05: And our next question comes from Joanne Wench from Citigroup. Go ahead, Joanne.
spk08: Good evening or afternoon, and thank you. I'm a little bit curious about some of the reimbursement landscape and things which may or may not have changed. Where do you think reimbursement is for BOLUS, and are you seeing any other changes as it relates to prior authorization or one product versus another or anything else that we really should be aware of? Thank you.
spk06: Thanks, Joanne. Yeah, I can take the question. So in terms of basal, we continue to make progress there. So, you know, as you think about where we're having the conversations, the conversations are both on the government in the U.S., CMS, as well as the U.S. commercial providers. We're having conversations with both, and our access team has submitted the data. They've submitted both clinical data, economic data, as well as clinician recommendations. And so we are going through those conversations. So it's been submitted. Discussions are ongoing. Timing is hard to peg in all of these, but we are continuing to advance it forward in terms of conversation. So that's basal. We'll certainly be, as that progresses forward, we'll continue to give you line of sight as to how that goes. In terms of other areas, so existing coverage in areas around prior authorizations or otherwise, we haven't seen a lot of that. Now, there are occasionally plans that have a prior authorization pop up or pull out. Our goal is through all of the renegotiations that take place to limit those prior authorizations. And as we continue to show how it CGM can improve patient outcomes. It's becoming very, very clear that prior authorizations, you know, we see payers starting to pull those down over time, better way to put it. And so we continue to expect to see and keep pushing that. We have not seen a material change in any form or factor. In fact, for the most part, we see them coming down, and we'll expect to see that over time in the intensive space.
spk05: And our next question comes from Matthew O'Brien. Go ahead, Matt.
spk04: Great. Thanks for taking the question. Um, can we just, you know, as I look at the stock down, you know, 18% in the aftermarket, that's 6 billion in lost market cap, even a little bit more than that. So, you know, I think it'd be helpful. I don't know if the reduction of the top line guidance from 20 down to 19, or maybe it's a little bit more as largely because of G7, but I'm thinking it's like a $60 million headwind, maybe something like that this year versus not getting the approval. So is it about $100 million of incremental pressure you're going to see next year and not having the approval earlier this year that you can't get all the marketing activities up and going next year? Just how do we frame up some of this modest delay? It seems like on the payer side things are better, but just frame up what this modest delay may do to the top line as we look forward.
spk06: Sure, I can talk about at least for 2022 and how it operates, and we can maybe not get too, too much into 2023, but it can help that conversation. So a lot of the guidance and the pull-down of guidance is related to currency, so it's not necessarily related to the G7 and the timing associated with that. So as you look at where we're going and where we've pulled that down, currency has, especially outside the U.S., has played a large impact on reported growth rates, and that's one of the reasons why we've shifted in how we talk about organic growth As you zoom back into the U.S., the G7 delay does have a little bit of an impact on guidance. And so certainly we would recognize that we had some impact in there and assumed it would launch. The longer term impact is really determined on how fast we get commercial coverage and how fast we can roll it out. And so what we believe is by working alongside our coverage teams and trying to get access as fast as possible and while we're working through getting formal approvals, partnering with folks to get quicker access and quicker coverage, We believe we can work on getting those patients back in quicker and faster to where we don't believe it's going to be a material impact on 2023 and beyond. And so a little bit in 2022, certainly it could have a little bit of tick in 2023, but for the most part, we're doing all the work now to make sure that we have a major launch where it doesn't impact longer-term growth rates.
spk05: And our next question comes from Jason Bedford from Raymond James. Go ahead, Jason.
spk15: Good afternoon. Just two questions that require quick answers. Just a clarification. I get the sense that it was a record for new patient starts in both the US and worldwide, if you could just confirm that. And then the second question is, you mentioned expanding the G7 launch. in Europe over the coming weeks, and I wasn't clear whether you're going into new countries or is this just more expansive in the U.K.? Thanks.
spk11: Yeah, this is Kevin. I'll start. Yes, it was record new patients OUS and in our U.S. markets as well. Both teams had new patient ad records during this quarter. With respect to the rollout of G7 in Europe, what we had indicated was our first rollout will be in the U.K., and we expect a rollout in other geographies before the end of the year.
spk05: And our next question comes from Travis Steed from Bank of America. Go ahead, Travis.
spk14: Hey, thanks for taking the question. One quick clarification, the pricing mix versus volume growth this quarter. And then as you look ahead to next year, will we start to see volume and revenue growth start to match up a bit more? And I'm thinking about the Basel opportunity. Is that an opportunity where you're going to have to lower price to get the volume? Or is the Basel pricing probably pretty similar to the intensive market? Thank you.
spk06: Sure. So I can take those questions. You know, in terms of pricing and what I would say is more channel mix, but the delta between the two, it was about the same this quarter as it was in prior quarter, which is what we had signaled at the start of the year. We still expect to migrate in the U.S. channel as we move more DME to pharmacy. That continues as expected. And then we had the OUS pricing where we took down pricing in exchange for access. We expected that to run through the end of Q2 before we lapped our strategy. So It's all gone in line with expectations. It was right around $70 million on the quarter. In terms of Basel and beyond, look, Basel coverage, we believe, is out there. In terms of what the pricing is, at this point, a lot of the conversations are about category coverage. And currently category coverage is already relatively defined, defined in pricing today. And so what that means is it could be the same, but would we be willing to talk to folks about increasing access in exchange for price? We'd absolutely entertain the conversation. It'd have to make sense for us for both, you know, the returns that we would expect on our performance as well as for our shareholders. But nothing to this point has indicated it would be lower. However, we understand that as more and more folks get access, we will be having those conversations.
spk05: And our next question comes from Marie Thiebaud from BTIG. Go ahead, Marie.
spk09: Hi, good evening. Thanks for taking the questions. I wanted to go back to something Kevin said earlier about the new software and app experience for the patient with G7 in the U.S. Can you give us a hint of how meaningful that new app experience might be for patient willingness to try the G7, to switch to the G7, what it might do for patient demand? Thank you.
spk11: One of the best features of the limited launch in the U.K. has been getting feedback on the software, and people absolutely love the app. From the very beginning when you start, it is much easier to fire it up and get on the system and understand what CGM is going to do for you and how it's going to work. So for a new user, this is a much, much easier experience and much, much easier start. The other thing that's very obvious in the software is another feature that our patients love. It's a 30-minute warm-up that actually ends up being about 25 minutes long. once you put the sensor on. I was speaking with a patient just last week, and I asked her, what is your favorite and what is your worst thing about G6? And the two-hour warm-up, as very frequently comes up, was what came up. And so this half-hour warm-up is going to be a feature. But the software itself, in addition to the typical graph and the sensor reading and the arrows, we also have clarity data built into the app that gives you feedback about how you're doing over one day, three days, seven days, or even a month. So someone can go down and look and see exactly how they're doing and what their trends are, you know, how much time they are spending in range. So it's much more of a full experience for somebody in their diabetes care, and our patients have liked it tremendously. We'll be ready to go on Android and iOS and launch. We're not going to hold either of them back. You know, the other thing with the app, and it's not really on the app, but it's a feature of this product that's been very well accepted as well, I didn't talk much about. We have a new receiver coming that the patients absolutely have loved and are using it very well. And while I, you know, I figured when we went to the phone in the beginning, everybody would immediately migrate to the phone. There's a very large percentage of our customers who use that receiver. They will be greatly enhanced in their experience by going to the next receiver. with us. And on the good news front as well, that new receiver, while a better experience, there's a much lower cost offering. So all good stuff there on the app.
spk05: And our next question comes from Matthew Blackman. Go ahead, Matthew.
spk01: Good afternoon, everybody. Thanks for taking my question. International growth did step up, even though you had a tougher comp. Is that the broader G7 rollout, Dexcom 1, some combination of those two? And I'm also really curious about Germany in particular, where I think you are going head-to-head versus the newest sensor from your competitor. Just any commentary about sort of geographic performance within that international number. Thanks.
spk06: Sure. Yeah, we can absolutely answer that. And, you know, it's interesting. Dexcom 1 and G7 really haven't contributed all that much to this point. So certainly it's an exciting future contributor, and we're very, very bullish on both G7 and the opportunity in Dexcom 1. Dexcom 1 really is in the bell countries and hasn't contributed all that much, and G7 with limited launch. And so what you're seeing is G7 with a more meaningful launch and Dexcom 1 with a more meaningful launch in bigger countries in Q3 and beyond. So what you saw in Q2 was really a continuation of our access and going deeper into countries where we had our G series, and really it was broad-based. And it's a continuation of broad-based performance outside the U.S., really across all of our countries, including Germany, where we do go head-to-head with Libre. free. And so I think what you can say is that business is doing incredibly well, and there's new catalysts to ultimately support it for upcoming periods. So we are very excited about that international business. And like I said, in countries where we're going up head to head with our competitors' most recent product, we continue to do very well and take share. So very, very bullish on our opportunity going forward.
spk05: And our next question comes from Josh Jennings from Cowen. Go ahead, Josh.
spk12: Hi, this is Brian here for Josh. Are you currently seeking or planning to seek CE Mark approval for the software changes you're making in the U.S.? And if so, could you share the projected timeline there? Thanks for taking the question.
spk11: We already have the software approved for CE Mark in Europe, and we do not plan immediately on implementing the changes that we're putting into the U.S. app, we'll consider that over time. We have the app and the software configured to whereby we can launch the product with what we're doing in Europe, sell it, and support it there. And if we feel the need to in some period of time, we can implement those changes into the other software and upgrade patients' apps on the phone, but not immediately, no.
spk05: Our next question comes from Stephen Lickman from Oppenheimer. Go ahead, Stephen.
spk02: Thank you. Hi, guys. As you're moving G7 to full launch in the UK, where you now also have Dexcom 1, I'm just wondering how will those two offerings be marketed relative to each other? Should we assume that over time they sort of merge, and with G7 becoming the primary hardware there, obviously that's going to happen in more and more countries over time. So I'm wondering if you could Talk to your thoughts on that. Thanks.
spk11: No, I appreciate that question. You know, we launched XCOM 1 in Europe and then we're launching in the UK because there are many reimbursement opportunities we've not been able to participate in. Our G series or our G6 and G7 products are regarded as very high end sensors for intensive insulin management, integration with insulin pumps, a lot of pediatrics, the share, the follow, the other features that have made our products so endeared to our users. The Dexcom One app doesn't have many of those features. It's much more simple, and it falls into a different reimbursement category in many of these geographies. In the UK, for example, our Dexcom One system will literally go through the pharmacy channel for broad-based distribution and broad-based accessibility for everybody, whereas our G-Series requires more documentation, more approval, and very specific conditions. As we look at these geographies, we think we have an opportunity with Dexcom 1 to sell a different product in a different system with different features that really won't step over onto our G-Series that is fully integrated with other systems and offers all these other features. Ultimately, as I said on the call, we want our Dexcom 1 product to be on the G7 platform as well as we simplify our operating structure over time, but that'll take a little while, and so G6 for Dexcom 1 platform we think will do very well, and our initial user feedback has been very good. The software for Dexcom 1, I would also add, has been designed on the same platform as the G7 software, so it looks and feels a little more, much more like G7 than it does G6, so our users will have a great experience there. As long as there are two reimbursement categories, we do not see these two products coming together from a reimbursement perspective. They might look more alike physically, and be on the same platform once we get G7 and enough capacity to transfer to the other Dexcom, one of that platform. But they won't be the same experience. It won't be reimbursed at the same rates.
spk05: And our next question comes from Larry Beagleson from Wells Fargo. Go ahead, Larry. Hi, this is Nathan on for Larry.
spk03: Can you comment on what drives the margin improvement in the second half, given the launch of G7, and how should we think about margins into 2023? Thanks.
spk06: Sure. Let me talk about the second half. And we won't get too, too much into 2023 specifically, other than we all have our long-range plan is 65%. And so that's the way we generally think about things. In terms of the back half of the year, Typically, what happens is, as we go typical seasonality, as we go through the course of the year, and part of this has to do with who's ultimately purchasing the product, margins typically get better. Now, that was thrown on its head a little bit as we were launching G7, and we had some timing things about when that would launch and what countries that would go into. So what you're finding is, is for the first half of the year, we actually had a few different unique items that impacted margins. What you're really finding is, is the run rate for our margin for the first half of the year, absentees, was just below 65. Back half of the year, we expect it to be just the opposite, just north of 65 as we hit that typical seasonality. We will have a little bit of pressure from the launch of G7 outside the U.S. However, that will clearly be offset through the G6 throughput that you ultimately see. And the reason the tick up in the back half of the year in some ways is due to With the G7 launch in a meaningful way inside the U.S. sliding into Q1 of next year, you do see that performance on that G6 platform, which continues to have nice margins play through over the course of the rest of the year. So we have a lot of confidence, 65% for the year, even despite all of the macroeconomic conditions.
spk05: We have no more questions at this time. I'll turn it back to the speakers for closing comments.
spk11: Well, again, thanks everybody for participating on the call. One of the great things that's happened in the second quarter has been my own ability to get out and talk and meet with people going to ADA and also some other conferences where I've spoken. And I've never seen Dexcom more respected and more visible than we are now. Our customer satisfaction scores, as I talked earlier, have never been higher and that's what you hear in real life. People are absolutely thrilled with the performance of our product and the problem that we solve for them. It's never been a better time here. We have a number of Dexcom 1 launches coming out over the next few quarters on top of that with G7 as well, both presenting great revenue and growth opportunities for us, and our operations are running very efficiently and smoothly. Everybody have a great day, and thanks for participating on the call.
spk05: Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect.
Disclaimer